DMAC
DiaMedica Therapeutics Inc

1,551
Loading...
Loading...
News
all
press releases
DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?
Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·3h ago
News Placeholder
More News
News Placeholder
After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks·8d ago
News Placeholder
Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade
The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·9d ago
News Placeholder
What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now?
Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·20d ago
News Placeholder
Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?
The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to an 114.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·29d ago
News Placeholder
DiaMedica Therapeutics Appoints Daniel J. OConnor to the Board of Directors
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of Daniel J. OConnor to its...
Business Wire·7mo ago
News Placeholder
DiaMedica Therapeutics Announces Publication of DM199s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed...
Business Wire·7mo ago
News Placeholder
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Companys...
Business Wire·7mo ago
News Placeholder
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today provided a business update and...
Business Wire·10mo ago
News Placeholder
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Companys...
Business Wire·10mo ago

Latest DMAC News

View

Advertisement. Remove ads.

Advertisement. Remove ads.